The use of combination antiretroviral therapy has proven remarkably effective in controlling HIV disease progression and prolonging survival. However, the emergence of drug resistance can occur. It is necessary that we gain a greater understanding of the evolution of drug resistance. Here, we consider an HIV viral dynamical model with general form of target cell density, drug resistance and intracellular delay incorporating antiretroviral therapy. The model includes two strains: wildtype and drug-resistant. The basic reproductive ratio for each strain is obtained for the existence of steady states. Qualitative analysis of the model such as the well-posedness of the solutions and the equilibrium stability is provided. Global asymptotic stability of the disease-free and drug-resistant steady states is shown by constructing Lyapunov functions. Furthermore, sufficient conditions related to the properties of the target cell density are obtained for the local asymptotic stability of the positive steady state. Numerical simulations are conducted to study the impact of target cell density and intracellular delay focusing on the stability of the positive steady state. The occurrence of Hopf bifurcation of periodic solutions is shown to depend on the target cell density.
Introduction

Human immunodeficiency virus (HIV) is a retrovirus that targets cells with CD4
+ receptors in the human body, including CD4 + T-cells, the main driver of the immune response. When the number of the CD4 + T-cells falls below a critical threshold an HIV patient is diagnosed with AIDS. Progression to AIDS can be controlled with the use of highly active antiretroviral therapy (HAART), combining reverse transcriptase inhibitors (RTIs) and protease inhibitors (PI) [49] which block the infection of target T-cells and cause infected cells to produce noninfectious virus particles respectively. HIV is a controllable infection, for the most part, in countries where a wide range of antiviral drugs are available. Unfortunately, the effectiveness of antiretroviral therapy (ART) can be remarkably reduced by the emergence of drug resistance [4, 46] . With the high replication rate (on average 10 10 particles per day [33] ) and the high mutation rate (3 × 10 −5 per base per replication cycle [24] ) of HIV, coupled with poor adherence to the treatment protocol, poor absorption and pharmacokinetics, drug resistant mutations are likely to appear in most patients [17, 41] , which will lead to a diagnosis of AIDS if new drug therapy regimens cannot be prescribed. It is imperative that the conditions that favor the evolution of drug resistance under HAART be uncovered and understood, so that HIV progression can be controlled. Mathematical models have been used to study HIV dynamics in-host, including the emergence of drug resistant mutations [1, 2, 8, 23, 30, 36, 37, 40, 44] . A limitation of these previous studies however, is that the effects of the viral eclipse phase on the viral life cycle (the intracellular delay between initial infection and release of new virus particles) have been ignored. Previous studies of the viral eclipse phase not including the emergence of drug resistance, have shown that the half-life of free virus can be reduced considerably [14] and that the infected cell loss rate may be increased [29] if a discrete intracellular delay is included in the model. Furthermore, it has been shown that the predicted rate of decline in plasma virus concentration depends on three factors: the death rate of virus producing cells, the efficacy of therapy, and the length of the intracellular delay, which can be anywhere from a few hours to 2 days depending on the drugs [10] . Thus, it is necessary to include an intracellular delay in models of the evolution of drug resistance.
A further limitation of previous models is that target cell dynamics are mainly described using a linear growth rate, ignoring the effects of proliferation and density dependence in the T-cell population [1, 2, [8] [9] [10] 14, 16, 18, [21] [22] [23] 29, 31, 33, 34, 36, 37, 40, 44, 50] . However, the proliferation rate of T-cells is density-dependent, with the rate of proliferation slowing as T-cell count increases [15, 38] . Some studies have assumed a logistic growth term including proliferation [6, 9, 18, 19, 22, 32, 33, 42, 43, 48] . With the exception of [22] , which found that the underlying mechanism for sustained oscillations in within-host viral models is the target cell proliferation rather than intracellular delay [22] , the combined effects of intracellular delay and logistic growth have not been studied. Such oscillations may have a profound impact of the evolution of drug resistance.
We have developed a system of delay differential equations incorporating an intracellular delay, logistic growth and antiretroviral therapy. This model is used to study the effects of cell density and time delay on the evolution of drug resistance under antiretroviral therapy. The paper is organized as follows. In Section 2, we construct our model and show the well-posedness of the model solutions (a disease-free equilibrium, a drug-resistant strain only equilibrium and a positive equilibrium where both strains exist). Two basic reproductive ratios with drug-sensitive and drug-resistant strain are given to ensure the existence of positive steady state. We employ Lyapunov functions to prove the global stability of disease-free steady state and drug-resistant strain steady state in Section 3. Moreover, we investigate the local asymptotic stability of the positive steady state for the time delay and we extend our stability analysis of drug-resistant strain and positive steady states respectively. Numerical simulations are used to demonstrate the effect of the target cell density and the intracellular delay on the model dynamics. Finally, we conclude our work and identify future avenues of study.
Model
Here, we derive a two-strain model with antiretroviral therapy. The model includes uninfected CD4 
T-cells (T ), productively infected CD4
+ T-cells (T * ) and infectious virus (V ). To include drug resistance, we divide the infectious virus and productively infected cell classes into drug-sensitive infectious virus (V s ), drug-resistant infectious virus (V r ), drug-sensitive infected CD4 + T-cells (T Fig. 1 . Model schematic. The schematic diagram of HIV transmission with drug-sensitive and drug-resistant strains during ART (without the intracellular delay).
with initial values
where, ψ 2 and ψ 4 are given non-negative constants,
The model is described as follows: uninfected CD4 + T-cells have a proliferation dependent growth rate f (T (t)) (see the following assumptions (A1)-(A3) for detail). It is assumed that the infection rates k s and k r , representing the infection of uninfected CD4 + T-cells by drug-sensitive and drug-resistant virus, may differ.
When infection occurs an infected CD4 + T-cell is produced after τ time. Here, τ represents a time delay between initial virus entry into a cell and subsequent viral production and the factor e −mτ is the probability that an infected CD4 + T cell survives the interval τ [10, 14, 16, 18, 21, 47, 50] , where 1/m is the average lifetime of infected CD4 + T-cells before they become productive. During the initial stages of infection, mutation from the drug-sensitive to the drug-resistant strain may occur with probability u (0 < u < 1). Back mutation from the drug-resistant to the drug-sensitive strain is ignored similar to [2, 30, 36, 44] . 
whereT denotes the number of the healthy CD4 + T-cells at each steady state. Assumptions (A1) and (A2)
imply that the disease-free systemṪ (t) = f (T (t)) has a globally asymptotically stable steady state T 0 , and (A3) assumes that the local or global asymptotic stability of each steady state of system (1). These assumptions are needed to properly reflect the disease states in individuals i.e. individuals that are disease free are in a stable state, and individuals infected with HIV are chronically infected.
Results
For convenience of notation in the following analysis let
By the basic theory of functional differential equations (see Theorem 2.3 in [12] ), there is a unique solution By the second and fourth equations in (1)
Similarly, from the third and fifth equations in (1),
. . we can then obtain the non-negativeness of solutions for all t 0.
As for boundedness of the solution, assumptions (A1) and (A2) and the first equation of system (1) imply that lim sup T (t) T 0 , t → +∞. We define
and h = min{1, δ/2, c}. Calculating the derivative of G(t) along the solution of system (1), we obtain
r and V r M/ρ for large t. This implies that the solution X(t) is ultimately bounded, completing the proof of the theorem. 2
The dynamics of system (1) will be analyzed in the following bounded feasible region
The argument in Theorem 3.1 shows that Γ is attractive. Moreover, sinceṪ (t) 0 when T (t) = T 0 the solution remains in Γ with t t . Similarly,Ṫ * s (t) 0 whenṪ * s (t) = M/ρ and the solution remains in Γ with t t . In the same manner it can be shown for all populations that the solution remains in Γ . Therefore, we conclude that Γ is positively invariant with respect to system (1).
Basic reproductive ratio
We use the survival method [13] to find the basic reproductive ratio, which is defined as the total number of newly infected cells produced by a single infected cell when introduced into a population of healthy T-cells [13, 31] . Let R s and R r denote the basic reproductive ratios of only drug-sensitive and only drug-resistant strains with drug therapy, respectively, where
and T 0 denotes the uninfected T-cell population when there is no virus in the system. We define
Biologically, if σ < 1, the drug-resistant strain dominates, while the drug-sensitive dominates if σ > 1. If there is no intracellular delay (τ = 0), R s and R r reduce to the basic reproductive ratios of model [30, 36] if term 1 − u is included in their R s . It is obvious that an intracellular delay decreases R s and R r . This implies that ignoring the intracellular delay τ in a viral model will overestimate R s and R r , however, the delay (τ ) has no effect on determining which strain dominates.
Steady states
System (1) always has one disease-free steady state E 0 (T 0 , 0, 0, 0, 0), where
System (1) also has a boundary steady state E r (T r , 0, 0, T * rr , V rr ) (only the drug-resistant strain is present) if R r > 1, where
A 
Note that, if u = 0 (no mutation from wild-type to mutant), the positive steady state E e reduces to another boundary steady state E s (T s , T * ss , V ss , 0, 0) where only the drug-sensitive strain is present. Here, R s > 1 and
E 0 and E r are unchanged when u = 0.
Global stability of E 0 and E r steady states
To study the stability at the steady stateĒ(T ,T *
where
The linearization of system (1) 
Let Y = e ξt be a solution of Eq. (3). Then, we obtain,
where I is the identity matrix. The characteristic equation of linearized system (4) at a steady stateĒ then becomes: Proof. The characteristic equation of the linearized system (4) at the disease-free steady state E 0 is
Clearly, ξ = −α 0 = f (T 0 ) < 0 (assumption (A1)) is a negative root of Eq. (5). The remaining roots of Eq. (5) are determined by the following transcendental equation
Substituting τ = 0 into Eq. (6) we obtain the following quartic equation:
Using the Descartes' rule of signs, it is obvious that the quartic equation (7) with τ = 0 has four negative real roots if R s < 1 and R r < 1.
Separating the real and imaginary parts of Eq. (6), and squaring and adding, we obtain two equations related with ω(τ ):
Notice that c > (1 − u)N sks T 0 e −mτ and c >N rkr T 0 e −mτ when R s < 1 and R r < 1, respectively. Clearly, Eqs. (8) have no positive roots. That is to say, there is no root that can across the imaginary axis of Eq. (5). Therefore, the disease-free steady state is locally asymptotically stable for τ 0.
For the case R s > 1 or R r > 1, Eq. (6) has at least one positive root with τ = 0. So, E 0 is unstable for τ = 0. When τ > 0, 
The derivative of W 1 along solutions of system (1) iṡ
If R s < 1 − u and R r < 1, we obtainẆ 1 0. ThusẆ 1 = 0 if and only if V s (t) = V r (t) = 0. The maximum invariant set in {ψ ∈ Γ |Ẇ 1 = 0} is the singleton E 0 . The LaSalle's invariance principle [20] implies that all solutions converge to E 0 . This and the local stability of E 0 established in Theorem 3.2 imply the global asymptotic stability of E 0 . 2 Proof. The characteristic equation of the linearized system (4) at the steady state with the only drugresistant virus E r is
Clearly, the characteristic equation (9) is determined by the following two equations
where,
Notice that part of the coefficients are dependent on the delay τ in characteristic equation (6), since T r includes τ .
We first consider the above equations with τ = 0, then
Using Routh-Hurwitz criterion, we easily get E r is locally asymptotically stable with τ = 0 since
and assumption (A3) implies that f (T r ) < 0. If τ > 0, let ξ = iw(τ ) with w(τ ) > 0. Substituting ξ with iw(τ ) into Eqs. (10), by simplification, we obtain the following
It is obvious to see that there are no positive roots ω(τ ) existing in (11) , and thus the characteristic equation (9) has no purely imaginary roots. Also, zero is not a root of Eq. (9). Therefore, E r is locally asymptotically stable for all delay τ 0. This completes the proof. 2
Next, we will establish a Lyapunov function to show the global stability of the drug-resistant steady state E r . 
Calculating the derivative of W 2 along with the solution of system (1), we obtaiṅ
Using the equalities f (T r ) =k r T r V rr = e mτ δT * rr ,N r δT * rr = cV rr at E r into the above equation, by simplification, theṅ
− e mτ δT * rr 
.
From assumption (A3), (f (T (t))
are satisfied. Thus, the maximum invariant set in {ψ ∈ Γ |Ẇ 2 = 0} is the singleton E r . Therefore, all solutions in Γ with non-negative initial values converge to E r by the LaSalle's invariance principle [20] . This and the local stability of E r established in Theorem 3.4 imply the global asymptotic stability of E r for all given τ 0. This completes the proof. 2
By Theorems 3.3 and 3.5, the global stability of the disease-free and drug-resistant only steady states have been obtained through constructing Lyapunov functions. These results imply that the intracellular delay has no effect on the occurrence of sustained oscillations for the well-defined growth rate f (T ). This conclusion is an extension of [16, 21, 22 ] that do not consider drug resistance.
Stability at E e
Consider the interval τ ∈ [0, τ max ), where τ max is the maximum value for the existence of positive steady state E e and τ max = 
Clearly, the characteristic equation (12) is determined by the following two equations
Notice that part of the coefficients are dependent on the delay τ in characteristic equation (13) , since T e includes τ . Consider Eq. (13) with τ = 0, then
Assumption (A3) implies that f (T e ) < 0. Therefore,
Using Routh-Hurwitz criterion, we easily obtain that E e is locally asymptotically stable with τ = 0. Next, we investigate the existence of purely imaginary roots ξ = iy with y > 0 if τ > 0, noticing that y is related to τ . Substituting ξ with iy into Eq. (13), we obtain:
Obviously, if σ > 1 and assumption (A3) are satisfied, then D 1 (0) = e (14), and thus the characteristic equation (12) has no purely imaginary roots. Also, zero is not a root of Eq. (12). Therefore, E e is locally asymptotically stable for all delay τ 0. This completes the proof. 2
Extension of the stability results, when u = 0
Sections 3.3 and 3.4 discuss the stability of system (1) equilibria when 0 < u < 1 of system. Now, we consider the stability results for the special case when u = 0.
When u = 0, the positive steady state E e reduces to the drug-sensitive only strain steady state E s if R s > 1 (see Section 3.2). By Theorems 3.2-3.5 and Theorem A.1 in Appendix A, we can easily obtain the corresponding stability results for the case u = 0. All the stability results for system (1) are summarized in Fig. 2 . Now, let us go back to the situation 0 < u < 1 of system (1). In Section 1, we introduced two well-accepted forms of target-cell dynamics f (T ) = λ − dT with a linear growth rate and
with logistic growth proliferation, where λ is the recruitment rate, d is the natural death rate of healthy CD4
+ T-cells, r is the growth rate and T max is the carrying capacity of the T-cell population. Obviously, the linear form with f (T ) = −d < 0 satisfies assumption (A3), while the logistic growth form with f (T ) = r − d − 2T /T max does not always satisfy (A3). In our whole proof of Theorems 3.4 and 3.7, we assume (A3) f (T ) < 0 is satisfied, however, we did not consider the case f (T ) > 0. So, even if f (T ) > 0 and f (T )/T − 2f (T ) > 0, then we can obtain the same results as Theorems 3.4 and 3.6. 
Numerical simulation
We perform numerical simulations to study the effects of the target cell density and intracellular delay on the viral dynamics during drug therapy.
Analytically, in Section 3.4, we found that the interval of the intracellular delay τ ∈ (0, τ max ) where
). Biologically, the accepted maximum value of τ is 2 days under drug therapy [10] . Therefore, we conduct our simulations considering an interval τ ∈ (0,τ ), whereτ = min(2, τ max ). The death rate of infected but not yet productive T-cells, m, is in general larger than the death rate of uninfected T-cells, d, since immune responses can target viral proteins presented on infected cells early on during the course of infection and effectively kill infected cells before they become productive. The precise value of m, however, remains unknown. For simplicity, we let m = d [10] in the following simulations.
To compare the model with and without the intracellular delay we consider f = λ − dT and the Data1 values (r = 0 and T max = 0) in Table 1 . Here, f = −d < 0, R s > 1 and σ > 1 and the hypotheses of Theorem 3.6 are satisfied, therefore, the positive steady state E e is always locally asymptotically stable on the interval τ ∈ (0,τ ). Fig. 3 demonstrates that the intracellular delay prolongs the time to peak for every population. It also shows that the delay has no effect on the stability of the positive steady state E e .
To study the effects of proliferation on the model populations we consider the T-cell dynamics with and without proliferation, f = λ − dT + rT (1 − T /T max ) where r = 0, 0.03, 0.3, 2. Fig. 4 demonstrates that for some parameter values the positive equilibrium (except for the uninfected cell count, since it is not affected by the growth rate r), decreases as r decreases, but the stability of E e is maintained (left column). However, for other sets of parameter values changes in r may induce periodic oscillations (right column). This is indicative of the existence of a Hopf bifurcation. Note that, when the proliferation rate r decreases, the average viral load and infected cell count decrease (Fig. 4, both columns) . Thus, the viral load and infected cell count are underestimated when a value of r = 0 is assumed. Thus, the true level of drug resistant virus would be missed, which would greatly affect the success of any ART regimen.
Figs. 3 and 4 demonstrate that the stability of E e depends on the target cell density, causing sustained oscillations as r increases, and not the intracellular delay. This agrees with Li and Shu [22] who studied the impact of intracellular delays and target-cell dynamics on in vivo viral infections. Table 1 .
Conclusion
We have studied an HIV model including a general form of target cell density, an intracellular delay and drug resistance under ART. Analytically, we obtained two basic reproductive ratios for the drug-sensitive and drug-resistant strains, and established sufficient conditions (corresponding to the two basic reproductive ratios) for global asymptotic stability of the disease-free (E 0 ) and drug-resistant (E r ) steady states. Moreover, we proved the local asymptotic stability of the positive steady state (E e ) under two different properties of target cell density. Numerically, we demonstrated the average viral load and infected cell count can be underestimated if the T-cell proliferation rate r is ignored. We also demonstrated that sustained oscillations can be induced under certain conditions when the proliferation rate r > 0. Our simulations indicate that the occurrence of these oscillations mainly depends on the target cell density, rather than the intracellular delay which the previous authors have done [6, 19, 43, 48] .
Sustained oscillations are indicative of the existence of a Hopf bifurcation. Our model exhibits these oscillations in biologically meaningful parameter space. This will affect the evolution of resistance and the success of any ART regimen since these oscillations demonstrate a rapid turnover of viral strains. Previous studies [3, 43, 45] have also found that sustained oscillations may exist in realistic parameter space for HIV. Ciupe et al. [3] explained that the delay model with an immune response leading to sustained oscillations arguably fits the clinical data better than the basic HIV model by Monte Carlo simulations. Wodarz et al. [45] also admitted sustained oscillations biologically for certain parameter values in a dynamical HIV model with an immune response.
System (1) does not consider the cytotoxic T lymphocyte (CTL) population. CTL play a critical part in antiviral defense by attacking virus-infected cells. It is believed that CTL are the main host immune factor that limits the extent of virus replication in vivo and thus determines the viral load [31] . An extension to our model involving the effects of CTL will be an avenue for future work. Future work will also involve a study of the effect of different treatment regimens on the emergence of resistance. .
From assumption (A3), we know that (f (T (t)) − f (T s ))(1 − are satisfied. It means the maximum invariant set in {ψ ∈ Γ |Ẇ 3 = 0} is the singleton E s . Therefore, all solutions in Γ with non-negative initial values converge to E s by the LaSalle's invariance principle [20] . This and the local stability of E s imply the global asymptotic stability of E s for all given τ 0. This completes the proof. 2
